144 related articles for article (PubMed ID: 27554081)
21. FAK loss reduces BRAF
Gao C; Ge H; Kuan SF; Cai C; Lu X; Esni F; Schoen R; Wang J; Chu E; Hu J
Res Sq; 2024 Jan; ():. PubMed ID: 36778401
[No Abstract] [Full Text] [Related]
22. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
Park JH; Devlin S; Durham BH; Winer ES; Huntington S; von Keudell G; Vemuri S; Shukla M; Falco V; Cuello B; Gore S; Stone R; Abdel-Wahab O; Tallman MS
NEJM Evid; 2023 Oct; 2(10):EVIDoa2300074. PubMed ID: 38320179
[TBL] [Abstract][Full Text] [Related]
23. A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: Case Report and Literature Review.
Ito K; Harada K; Uchino Y; Hirano K; Sekiguchi N
Acta Haematol; 2023 Nov; ():. PubMed ID: 37952510
[TBL] [Abstract][Full Text] [Related]
24. Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors.
Otieno SB; Nasir S; Weir A; Johnson R
Case Rep Hematol; 2020; 2020():8821415. PubMed ID: 33381330
[TBL] [Abstract][Full Text] [Related]
25. BRAF-negative, CD103-negative hairy cell leukemia.
Jimenez A; Shuai W
Blood; 2023 Feb; 141(7):806. PubMed ID: 36795444
[No Abstract] [Full Text] [Related]
26. Clinical analysis of hairy cell leukemia: the rare indolent hematological malignancy.
Huang H; Liu Y; Zeng M; Chen X; Yin Y; Guo H; Yan Z; Lin J
Am J Transl Res; 2024; 16(2):466-476. PubMed ID: 38463575
[TBL] [Abstract][Full Text] [Related]
27. Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK.
Hey F; Andreadi C; Noble C; Patel B; Jin H; Kamata T; Straatman K; Luo J; Balmanno K; Jones DTW; Collins VP; Cook SJ; Caunt CJ; Pritchard C
Heliyon; 2018 Dec; 4(12):e01065. PubMed ID: 30603699
[TBL] [Abstract][Full Text] [Related]
28. Hairy cell leukemia - immunotargets and therapies.
Basheer F; Bloxham DM; Scott MA; Follows GA
Immunotargets Ther; 2014; 3():107-20. PubMed ID: 27471703
[TBL] [Abstract][Full Text] [Related]
29. MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.
Chakraborty R; Abdel-Wahab O; Durham BH
Cold Spring Harb Perspect Med; 2021 May; 11(5):. PubMed ID: 32601132
[TBL] [Abstract][Full Text] [Related]
30. Detangling the Threads of Hairy Cell Leukemia, Beyond the Morphology and Into the Molecular.
Brazel D; Hermel D; Gandhi P; Saven A
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38849281
[TBL] [Abstract][Full Text] [Related]
31.
Abuasab T; Mohamed S; Pemmaraju N; Kadia TM; Daver N; DiNardo CD; Ravandi F; Qiao W; Montalban-Bravo G; Borthakur G
Leuk Lymphoma; 2024 May; ():1-6. PubMed ID: 38696743
[TBL] [Abstract][Full Text] [Related]
32. Non-V600E
Vijayanarayanan A; Wang SA; Garces S; Saluja K; Medeiros LJ; Thakral B
EJHaem; 2024 Feb; 5(1):266-268. PubMed ID: 38406543
[No Abstract] [Full Text] [Related]
33. Recent advances in understanding and managing hairy cell leukemia.
Roider T; Falini B; Dietrich S
F1000Res; 2018; 7():. PubMed ID: 29770206
[TBL] [Abstract][Full Text] [Related]
34. Genomics of Hairy Cell Leukemia.
Tiacci E; Pettirossi V; Schiavoni G; Falini B
J Clin Oncol; 2017 Mar; 35(9):1002-1010. PubMed ID: 28297625
[TBL] [Abstract][Full Text] [Related]
35. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Grever MR; Abdel-Wahab O; Andritsos LA; Banerji V; Barrientos J; Blachly JS; Call TG; Catovsky D; Dearden C; Demeter J; Else M; Forconi F; Gozzetti A; Ho AD; Johnston JB; Jones J; Juliusson G; Kraut E; Kreitman RJ; Larratt L; Lauria F; Lozanski G; Montserrat E; Parikh SA; Park JH; Polliack A; Quest GR; Rai KR; Ravandi F; Robak T; Saven A; Seymour JF; Tadmor T; Tallman MS; Tam C; Tiacci E; Troussard X; Zent CS; Zenz T; Zinzani PL; Falini B
Blood; 2017 Feb; 129(5):553-560. PubMed ID: 27903528
[TBL] [Abstract][Full Text] [Related]
36. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
37. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
Troussard X; Cornet E
Am J Hematol; 2017 Dec; 92(12):1382-1390. PubMed ID: 29110361
[TBL] [Abstract][Full Text] [Related]
38. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Durham BH; Getta B; Dietrich S; Taylor J; Won H; Bogenberger JM; Scott S; Kim E; Chung YR; Chung SS; Hüllein J; Walther T; Wang L; Lu SX; Oakes CC; Tibes R; Haferlach T; Taylor BS; Tallman MS; Berger MF; Park JH; Zenz T; Abdel-Wahab O
Blood; 2017 Oct; 130(14):1644-1648. PubMed ID: 28801450
[TBL] [Abstract][Full Text] [Related]
39. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG; Byrd JC; Abramson JS; Bhat S; Bociek G; Brander D; Brown J; Chanan-Khan A; Coutre SE; Davis RS; Fletcher CD; Hill B; Kahl BS; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Lancet J; Ma S; Malek S; Mosse C; Shadman M; Siddiqi T; Stephens D; Wagner N; Zelenetz AD; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2017 Nov; 15(11):1414-1427. PubMed ID: 29118233
[TBL] [Abstract][Full Text] [Related]
40. 2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Teras LR; DeSantis CE; Cerhan JR; Morton LM; Jemal A; Flowers CR
CA Cancer J Clin; 2016 Nov; 66(6):443-459. PubMed ID: 27618563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
